Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

267
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
267
Drug Therapy01:28

Drug Therapy

96
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
96
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Biochemical and Biophysical Investigation of a Calmodulin-Like Protein From Glycine max Delineates Its Role as a Calcium Sensor During Herbivory.

Physiologia plantarum·2025
Same author

Parkin, a key player in Parkinson's disease pathogenesis: A review.

International journal of biological macromolecules·2025
Same author

Phytochemicals as potential AXL inhibitors for cancer therapy: A computational study.

Computational biology and chemistry·2025
Same author

Aggregation-Prone Pathogenic SOD1 Variants in Amyotrophic Lateral Sclerosis: Insights from Computational Genomics and Evolutionary Conservation.

Journal of molecular neuroscience : MN·2025
Same author

Structure-based identification of bioactive compounds as trace amine-associated receptor 1 agonists for the therapeutic management of major depressive disorder.

PloS one·2025
Same author

Insights into Caspase-6 Mutations and Neuropathology in Huntington's Disease and Psychiatric Disorders: A Structural Genomics and Drug Repurposing Approach.

Molecular neurobiology·2025

相关实验视频

Updated: Sep 9, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K

亨廷顿病的治疗策略:目前的方法和未来的方向

Mehak Gulzar1, Sana Kauser2, Sumaiya Khan1

  • 1Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.

Neurodegenerative disease management
|August 28, 2025
PubMed
概括

亨廷顿病 (HD) 治疗正在推进,重点是通过基因疗法和小分子降低突变亨廷丁 (mHTT) 水平. 需要进一步的研究来克服分娩和安全方面的挑战,以改善患者的治疗结果.

关键词:
在 CAG 中重复关于CRISPR的研究美国食品和药物管理局批准的药物亨廷顿病突变的狩猎蛋白质神经退行性疾病

更多相关视频

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.8K

相关实验视频

Last Updated: Sep 9, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.0K
Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.8K

科学领域:

  • 神经科学
  • 遗传学
  • 药理学

背景情况:

  • 亨廷顿病 (HD) 是一种渐进的遗传性神经退行性疾病.
  • 它源于亨廷顿基因的CAG三核酸扩张,导致毒性突变亨廷丁 (mHTT) 在大脑中积累.
  • 疾病表现为运动,认知和精神障碍.

研究的目的:

  • 对亨廷顿病的治疗策略进行审查.
  • 探索包括小分子,基因疗法和蛋白质降解技术在内的新方法.
  • 评估像VTX-003和ANX005这样的特定药物的潜力.

主要方法:

  • 现有HD治疗研究的文献综述.
  • 分析小分子方法,基因疗法 (例如基于CRISPR) 和蛋白质降解技术.
  • 评估针对减少mHTT的新兴疗法.

主要成果:

  • 多种治疗策略有望降低mHTT水平.
  • 基于CRISPR的方法和小分子向蛋白质降解是开发的关键领域.
  • 目前正在研究VTX- 003和ANX005是否有可能减缓疾病的进展.

结论:

  • 在开发亨廷顿病治疗方面取得了显著进展.
  • 长期有效性,药物输送和尽量减少非目标效应仍然是挑战.
  • 加强治疗干预对于改善患者生活质量至关重要.